NCT Number: NCT06182956
The objectives of this study are to compare the physiological consequences of high-flow oxygen therapy and noninvasive mechanical ventilation on ventilation, respiratory work and hemodynamics during acute respiratory failure in diffuse interstitial pneumonia.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Rouen, 76000, France
Antoine CUVELIER, MD, PHD
SUB_INVESTIGATOR
Christophe GIRAULT, MD
SUB_INVESTIGATOR
David DEBEAUMONT, MD
SUB_INVESTIGATOR
Elise ARTAUD-MACARI, MD
CONTACT
Gurvan LEBOUAR, MD
SUB_INVESTIGATOR
Pierre Alexandre ROGER, MD
SUB_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Noninvasive mechanical ventilation is a respiratory technique which allows the administration of positive inspiratory and expiratory airway pressures in order to ventilate the lungs.
Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen.
Continuous positive airway pressure is a respiratory technique which allows to maintain a constant positive airway pressure during inspiration and expiration.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of global pulmonary compliance (Cglob) under noninvasive ventilation (NIV) and high-flow oxygen therapy (HFO) during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of global pulmonary compliance (Cglob) under NIV and continuous positive airway pressure (CPAP) during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of global pulmonary compliance (Cglob) under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of global pulmonary compliance (Cglob) under HFO and face mask oxygen therapy (FM) during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of global pulmonary compliance (Cglob) under NIV and face mask oxygen therapy (FM) during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of global pulmonary compliance (Cglob) under CPAP and face mask oxygen therapy (FM) during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Tidal volume under CPAP and face mask oxygen therapy (FM) during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Tidal volume under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Tidal volume under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Tidal volume under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Tidal volume under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Tidal volume under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of end-expiratory lung volume under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of end-expiratory lung volume under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of end-expiratory lung volume under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of end-expiratory lung volume under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of end-expiratory lung volume under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of end-expiratory lung volume under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transpulmonary pressure under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transpulmonary pressure under FM and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transpulmonary pressure under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transpulmonary pressure under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transpulmonary pressure under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transpulmonary pressure under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of driving pressure under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of driving pressure under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of driving pressure under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of driving pressure under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of driving pressure under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of driving pressure under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Global inhomogeneity index under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Global inhomogeneity index under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Global inhomogeneity index under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Global inhomogeneity index under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Global inhomogeneity index under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Global inhomogeneity index under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of respiratory rate under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of respiratory rate under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of respiratory rate under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of respiratory rate under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of respiratory rate under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of respiratory rate under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of inspiratory time under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of inspiratory time under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of inspiratory time under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of inspiratory time under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of inspiratory time under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of inspiratory time under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of inspiratory time under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of oesophagal pressure variations between inspiration and expiration under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of oesophagal pressure variations between inspiration and expiration under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of oesophagal pressure variations between inspiration and expiration under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of oesophagal pressure variations between inspiration and expiration under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of oesophagal pressure variations between inspiration and expiration under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of oesophagal pressure variations between inspiration and expiration under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transdiaphragmatic pressure variations between inspiration and expiration under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transdiaphragmatic pressure variations between inspiration and expiration under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transdiaphragmatic pressure variations between inspiration and expiration under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transdiaphragmatic pressure variations between inspiration and expiration under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transdiaphragmatic pressure variations between inspiration and expiration under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transdiaphragmatic pressure variations between inspiration and expiration under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transdiaphragmatic pressure time products under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transdiaphragmatic pressure time products under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transdiaphragmatic pressure time products under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transdiaphragmatic pressure time products under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transdiaphragmatic pressure time products under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transdiaphragmatic pressure time products under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of oesophagal pressure time products under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of oesophagal pressure time products under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of oesophagal pressure time products under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of oesophagal pressure time products under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of oesophagal pressure time products under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of oesophagal pressure time products under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of ultrasound diaphragmatic strain under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of diaphragmatic thickening fraction under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of diaphragmatic thickening fraction under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of diaphragmatic thickening fraction under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of diaphragmatic thickening fraction under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of diaphragmatic thickening fraction under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of diaphragmatic thickening fraction under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of peak inspiratory flow under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of peak inspiratory flow under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of peak inspiratory flow under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of peak inspiratory flow under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of peak inspiratory flow under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of peak inspiratory flow under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of peak expiratory flow under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of peak expiratory flow under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of peak expiratory flow under FM and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of peak expiratory flow under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of peak expiratory flow under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of peak expiratory flow under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Systolic arterial pressures under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Systolic arterial pressures under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Systolic arterial pressures under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Systolic arterial pressures under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Systolic arterial pressures under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Systolic arterial pressures under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Diastolic arterial pressures under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Diastolic arterial pressures under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Diastolic arterial pressures under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Diastolic arterial pressures under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Diastolic arterial pressures under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Diastolic arterial pressures under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Mean arterial pressures under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Mean arterial pressures under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Mean arterial pressures under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Mean arterial pressures under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Mean arterial pressures under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Mean arterial pressures under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of systolic pulmonary arterial pressure under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of systolic pulmonary arterial pressure under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of systolic pulmonary arterial pressure under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of systolic pulmonary arterial pressure under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of systolic pulmonary arterial pressure under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of systolic pulmonary arterial pressure under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of tricuspid annular plane systolic excursion under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of tricuspid annular plane systolic excursion under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of tricuspid annular plane systolic excursion under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of tricuspid annular plane systolic excursion under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of tricuspid annular plane systolic excursion under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of tricuspid annular plane systolic excursion under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of right ventricular strain under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of right ventricular strain under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of right ventricular strain under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of right ventricular strain under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of right ventricular strain under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of right ventricular strain under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of left ventricular ejection fraction under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of left ventricular ejection fraction under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of left ventricular ejection fraction under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of left ventricular ejection fraction under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of left ventricular ejection fraction under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of left ventricular ejection fraction under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of E/E' ratio under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of E/E' ratio under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of E/E' ratio under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of E/E' ratio under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of E/E' ratio under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of E/E' ratio under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of right auricular pressure under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of right auricular pressure under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of right auricular pressure under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of right auricular pressure under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of right auricular pressure under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of right auricular pressure under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of cardiac output under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of cardiac output under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of cardiac output under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of cardiac output under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of cardiac output under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of cardiac output under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of heart rate under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of heart rate under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of heart rate under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of heart rate under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of heart rate under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of heart rate under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of pulsed oxymetry under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of pulsed oxymetry under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of pulsed oxymetry under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of pulsed oxymetry under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of pulsed oxymetry under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of pulsed oxymetry under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transcutaneous carbon dioxide pressure under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transcutaneous carbon dioxide pressure under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transcutaneous carbon dioxide pressure under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transcutaneous carbon dioxide pressure under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transcutaneous carbon dioxide pressure under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of transcutaneous carbon dioxide pressure under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Visual comfort scale (from 0 to 10, 10 is maximal confort) under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Visual comfort scale (from 0 to 10, 10 is maximal confort) under FM and HFO during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Visual comfort scale (from 0 to 10, 10 is maximal confort) under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Visual comfort scale (from 0 to 10, 10 is maximal confort) under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Visual comfort scale (from 0 to 10, 10 is maximal confort) under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.
Time frame: During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Visual comfort scale (from 0 to 10, 10 is maximal confort) under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.
Contact information is provided by the study sponsor or research team.
Elise ARTAUD-MACARI, MD
CONTACT
Maryline LEFORT
CONTACT
ADIR Association
Other
Evaluation of Physiological Effects of Noninvasive Mechanical Ventilation and High-flow Oxygen Therapy for Acute Exacerbations of Interstitial Lung Diseases
Acronym: IRAPIDPhysio
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05681962
Acute Respiratory Failure, Fibrosis
Catanzaro, Italy
View Trial DetailsNCT07728448
Cardiovascular Diseases, Connective Tissue Disease-associated Interstitial Lung Disease
View Trial DetailsNCT07714252
Cardiovascular Diseases, Chronic Disease
Phoenix, Arizona, United States
View Trial DetailsNCT07486869
Amyopathic dermatomyositis, Connective Tissue Diseases
Miami, Florida, United States
View Trial Details